Skip to main content

Vimta Labs


Vimta Labs is in the business of contract research and testing for the pharmaceutical industry.

The company has received national and international accreditations, been subject to audits by global regulators, and entered into partnerships with market leaders in the past.

It reported stable operating profits on steadily growing revenues until the last twelve months – when it reported marginal operating losses (instead of the usual profits before depreciation of 20 to 25cr) on revenues of about 90cr, primarily due to delays in approvals (see below) and increased costs of materials consumed in its operations.

The company’s debt load is high relative to recent cash flows and is largely dependent on collection of its receivables to pay it off.  It is therefore exposed to high interest rates as well as a depreciating INR in paying its domestic and foreign currency loans respectively. 

The auditors’ report revealed that the company has, in fact, defaulted in repayment of few of the instalments of the loans it owes – as suspected above.  This situation is unlikely to change unless receivables are collected in a timely manner and the below risks are mitigated in an effective manner.

The business is exposed to severe delays in receiving regulatory approvals for projects.  It is also subject to heavy competition from multi-national companies looking for a low cost base.

The business, by its very nature, requires continuous innovation in portfolios which precludes the building of sustainable competitive edge.  It also requires investments based on foresight – sometimes years in advance – that are subject to considerable risk of error.

Apart from the above, the business is exposed to changes in government regulations, high employee turnover in a rapid growth environment, and inflationary cost increases among other factors.

Comments

Post a Comment

Popular posts from this blog

On The Radar: India's Small-Cap Equities (Concluded)

We have been running a series of articles titled ‘Under The Radar: India’s Small-Cap Equities’ beginning in December 2011 - and followed up twice - with the last article in December 2013. We would like to conclude this series after updating the small-cap index level and returns, comparing it to our expectations ex-ante, and analysing the current scenario.  Following this, we have also outlined where we may take this blog in the future. The small-cap index closed at 11,087.07 on December 31 st , 2014.  This compares to a level of 6,150.65 in our last article – resulting in an advance of over 80% to date. This is a handsome absolute return by any standard, particularly compared to Indian government bonds, which yielded around 8-9% for the period.  This justifies the conclusion at the end of our previous article that “small-caps in India offer among the most attractive bargains during any time since 2006 and certainly in the entire Indian stock market today...
1 comment
Read more

IFB Agro Industries

IFB Agro Industries is in the business of producing alcohol (70% to 75% of revenues) and marine products. The company is based out of the state of West Bengal (WB), which is well known for its regressive attitudes towards businesses.  In the alcohol segment, it distributes ‘Volga’ vodka, ‘Jubilation’ rum, ‘Benjamin’ brandy (latter two launched recently).  Demand in the Indian Made Foreign Liquor (IMFL) appears to have a promising outlook with growth estimated at about 20% per annum.  It has also installed a new plant to enhance its country liquor production capacity since demand was outstripping supply – however, licenses weren’t granted by the state as at the end of last year.  In the marine segment, it distributes frozen marine products in the major metros through retail chains under the “IFB Royal” brand.  It also has a 48% market share in the shrimp feed trading business.  It had recently enhanced capacities in the marine division includi...
2 comments
Read more

Under The Radar: India’s Small-Cap Equities (Part Three)

In February of this year, we summarised the valuation parameters of the BSE Small-cap Index in India (now the S&P BSE Small Cap Index) - following on from an earlier report we wrote in December, 2011 - and drew certain conclusions. We would like to update the valuation scenario with the data today, review those conclusions, and form new ones based on the available information. The small-cap index closed today (17 th December, 2013) at 6,150.65 with an indicated price to book value of 1.04. The closing value as on February, 2013 was 7,006.73 representing a decline of over 12% as of today. The current index value masks a greater fall of over 27% to a low of 5,085.56 in August, 2013. This represents an unsatisfactory overall performance for those who invested in small caps at the beginning of the year. In our earlier report, we made two assumptions towards the end of our report to form a conclusion as to prices then:          ...
Post a Comment
Read more